Key Points
- Allogene Therapeutics CFO Geoffrey Parker sold 36,342 shares at an average price of $1.34, generating $48,698.28. The sale covered tax-withholding obligations tied to vested equity awards, leaving him with 1,045,877 shares.
- ALLO opened at $1.25 and has a market capitalization of approximately $431.9 million, trading well below its 52-week high of $4.46.
- The company exceeded quarterly expectations, reporting a loss of $0.13 per share versus the forecasted $0.17 loss and $4.64 million in revenue. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $8.30.
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) CFO Geoffrey Parker sold 36,342 shares of the firm's stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $1.34, for a total transaction of $48,698.28. Following the completion of the transaction, the chief financial officer directly owned 1,045,877 shares of the company's stock, valued at approximately $1,401,475.18. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Allogene Therapeutics Price Performance
ALLO opened at $1.25 on Friday. The firm has a market capitalization of $431.86 million, a P/E ratio of -1.87 and a beta of 0.56. Allogene Therapeutics, Inc. has a one year low of $1.04 and a one year high of $4.46. The company has a fifty day moving average price of $1.70 and a 200-day moving average price of $1.96.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.04. The business had revenue of $4.64 million during the quarter, compared to analysts' expectations of $0.00 million. On average, analysts expect that Allogene Therapeutics, Inc. will post -0.58 earnings per share for the current year.
Hedge Funds Weigh In On Allogene Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Private Wealth Services LLC bought a new position in shares of Allogene Therapeutics in the 1st quarter worth $27,000. Pallas Capital Advisors LLC purchased a new stake in shares of Allogene Therapeutics during the 2nd quarter valued at $25,000. Bull Harbor Capital LLC purchased a new stake in shares of Allogene Therapeutics during the 1st quarter valued at $31,000. GTS Securities LLC purchased a new stake in shares of Allogene Therapeutics during the 2nd quarter valued at $27,000. Finally, Krilogy Financial LLC bought a new stake in shares of Allogene Therapeutics during the 1st quarter worth $40,000. Hedge funds and other institutional investors own 83.63% of the company's stock.
Analyst Ratings Changes
A number of equities analysts have weighed in on ALLO shares. William Blair upgraded Allogene Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 23rd. Weiss Ratings raised Allogene Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday. Finally, Citizens Jmp reiterated a "market outperform" rating and set a $6.00 price target on shares of Allogene Therapeutics in a research report on Monday, August 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Allogene Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.30.
View Our Latest Stock Analysis on Allogene Therapeutics
Allogene Therapeutics Company Profile
(
Get Free Report)
Allogene Therapeutics, Inc is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” CAR T cell therapies for cancer. Unlike conventional autologous CAR T treatments, which are manufactured from an individual patient's own cells, Allogene's approach uses healthy donor cells that can potentially be produced in advance and administered more quickly.
The company's investigational pipeline has included cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A) for certain patients with large B-cell lymphoma, as well as other allogeneic CAR T candidates being studied in blood cancers such as multiple myeloma and in solid tumors, including renal cell carcinoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
